2011
DOI: 10.1021/cb200222s
|View full text |Cite
|
Sign up to set email alerts
|

A Chemically Induced Vaccine Strategy for Prostate Cancer

Abstract: Here we report the design and evaluation of a bifunctional, small molecule switch that induces a targeted immune response against tumors in vivo. A high affinity ligand for prostate specific membrane antigen (PSMA) was conjugated to a hapten that binds dinitrophenyl (DNP)-specific antibodies. When introduced into hu-PBL-NOD/SCID mice previously immunized with a KLH-DNP immunogen, this conjugate induced a targeted antibody-dependent cellular cytotoxicity (ADCC) response to PSMA-expressing tumor cells in a mouse… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
57
0

Year Published

2011
2011
2019
2019

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 46 publications
(59 citation statements)
references
References 23 publications
1
57
0
Order By: Relevance
“…These and other predictions arising from our model have already proven useful in the ongoing pre-clinical development of these compounds. 46 …”
Section: Resultsmentioning
confidence: 99%
“…These and other predictions arising from our model have already proven useful in the ongoing pre-clinical development of these compounds. 46 …”
Section: Resultsmentioning
confidence: 99%
“…Finally, cell-mediated cytotoxicity was dependent upon the presence of anti-DNP antibody; treatment of Hp with an isotype control antibody in place of anti-DNP led to only background levels of cell killing (Figure 5B). The specific cytotoxicity observed upon treatment with both azidosugar and phosphine (~25%) is on-par with what is required for cell killing in vivo [24] .…”
Section: Resultsmentioning
confidence: 99%
“…(50,51,52,53,54) Despite these successes, relatively few examples of using small-molecules to redirect antibody-mediated immune responses against cancers have been disclosed. (28,29,30,31,32,33,34,35) Some of these approaches have shown promising results in animal studies using anti-hapten-immunized mice(29,30,35,55) or with injected antibody(31,32,33). The approach reported here differs from these prior strategies in that it targets uPAR, which is found on a broad variety of invasive cancer cells, and it also has the potential to exploit the naturally-occurring, hapten-directed class of anti-DNP antibodies for cancer cell destruction.…”
Section: Resultsmentioning
confidence: 99%